Clinical trials: OHT - Ocular Hypertension
Open Angle Glaucoma
Clinical Evaluation of Visco-Assisted CyPass® Micro-Stent Implantation in Patients With Open Angle Glaucoma
The purpose of this study is to assess the safety and effectiveness of the use of visco-assisted CyPass® Micro-Stent implantation for the lowering of intraocular pressure (IOP) in subjects who have open angle glaucoma (OAG).
- Trial name
- ViscoPass (NCT02448875)
- Testing
- CyPass Micro-Stent, Viscoelastic
- Where
- 6 sites in Germany, Panama and 2 more
- Volunteers
- 192 people
- Sponsor
- Transcend Medical, Inc.
Open-angle Glaucoma, Ocular Hypertension
IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with…
- Trial name
- NCT00527501
- Testing
- Travoprost/brinzolamide
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Alcon Research
Adherence to Glaucoma Therapy
Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®
The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops using connected device…
- Trial name
- NCT07206628
- Where
- 15 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Laboratoires Thea
Open-angle Glaucoma, Ocular Hypertension
Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Eligible patients will be randomized in a 1.1 ratio to receive Travoprost 0.004%/timolol 0.5% once daily or Latanoprost 0.005%/Timolol 0.5% once a day for 8 Weeks.
- Trial name
- NCT00872651
- Testing
- Travoprost 0.004%/Timolol 0.5%, Latanoprost 0.005% / Timolol 0.5%
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
Safety and Efficacy of Changing to DuoTrav From Prior Therapy
The purpose of this study to assess the safety and efficacy of changing to DuoTrav® from prior bimatoprost 0.03%/timolol 0.5% (used concomitantly or in a fixed combination) pharmacotherapy in uncontrolled patients with open-angle…
- Trial name
- NCT01230736
- Testing
- Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT00061503
- Testing
- Travoprost
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
Evaluate the effectiveness of dorzolamide-timolol (Cosopt®) as first line therapy in reducing intraocular pressure in patients with untreated Open angle glaucoma (OAG) or Ocular hypertension (OH).
- Trial name
- NCT00546286
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: dorzolamide HCl/timolol maleate + prostaglandin
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Open Angle Glaucoma (POAG)
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
- Trial name
- NCT03478293
- Testing
- iStent inject surgery
- Where
- Brazil
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
The Effects of DSLT and SLT on the Corneal Endothelium: A GLAUrious Trial Sub-Study
The objective of this study is to compare the long-term (6 months) effects of Direct Selective Laser Trabeculoplasty (DSLT) treatment and SLT (Selective Laser Trabeculoplasty) treatment on corneal endothelial cell counts and…
- Trial name
- NCT04758598
- Testing
- Direct Selective Laser Trabeculoplasty (DSLT), Selective Laser Trabeculoplasty (SLT)
- Where
- Georgia
- Volunteers
- 20 people
- Sponsor
- BelkinVision
Glaucoma, Ocular Hypertension
Survey of Patients Taking IOP-Lowering Eye Drops
Survey to assess perspectives of patients prescribed IOP-lowering eye drops at a single office visit.
- Trial name
- NCT02384772
- Testing
- Survey
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- ForSight Vision5, Inc.
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM…
- Trial name
- NCT04405245
- Testing
- Latanoprost ophthalmic solution, AKB-9778 4%
- Where
- 21 sites in United States
- Volunteers
- 194 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Open-Angle, Ocular Hypertension
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.
- Trial name
- NCT02247804
- Testing
- Bimatoprost SR, Active Comparator: Timolol 0.5%
- Where
- 106 sites in United States, Australia and 12 more
- Volunteers
- 594 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Evaluation of Efficacy and Safety of Susanna Implant in Patients With Refractory Glaucoma.
Study clinical multicenter, phase III, open-label, prospective character to evaluate the efficacy and safety Susanna Implant in patients with refractory glaucoma.
- Trial name
- NCT01314170
- Testing
- Susanna Implant
- Where
- Brazil
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Adapt Produtos Oftalmológicos Ltda.
Primary Open Angle Glaucoma, Ocular Hypertension
ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects
This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension
- Trial name
- NCT01668524
- Testing
- ATS907
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Altheos, Inc.
Ocular Hypertension
An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension
The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.
- Trial name
- NCT00825396
- Testing
- C-KAD Ophthalmic Solution
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Chakshu Research, Inc.
Glaucoma, Open Angle, Ocular Hypertension
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension
- Trial name
- NCT00219596
- Testing
- Xalacom, unfixed Latanoprost and Timolol
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.